American Heart Association Promotes Statin Usage as Lipitor Lawsuit Litigation Heats Up

Published on November 20, 2013 by Sandy Liebhard

Text-Size:A A A+


The American Heart Association has issued new cholesterol guidelines that could affect about a quarter of the American population over the age of 40, but only time will tell whether new regulations will lead to more Lipitor lawsuit filings. According to the new guidelines, individuals whose “bad” cholesterol levels exceed 190 should be on medications to lower their cholesterol. Patients who fall below that range should only take statins if they have high blood pressure, diabetes, and other health risks that could increase their likelihood of a heart attack. A November 16th report from says the American Heart Association’s new guidelines could lead to statin use in 35 million more Americans. This information is troubling, given the increasing litigation of Lipitor diabetes lawsuits alleging serious injuries caused by the cholesterol-lowering medication. Plaintiffs who have filed cases that are currently pending in courts throughout the U.S. say they developed new-onset Type 2 diabetes after using the drug for a prolonged period of time.

At Least 100 Lipitor Lawsuit Claims Filed in U.S., Plaintiffs Seek Creation of MDL

Multiple petitions seeking the creation of a federal multidistrict litigation have been filed by individuals involved in Lipitor lawsuits. According to the most recently filed Motion with the U.S. Judicial Panel on Multidistrict Litigation (JPML), at least 100 claims had been filed as of October 28th, 2013. Earlier this year, the Panel vetoed a similar request from Plaintiffs on the grounds that only a handful of cases were pending in U.S. courts, and did not warrant the need for consolidation in a single proceeding.  Lipitor lawsuits allege the drug’s manufacturer, Pfizer Inc., failed to adequately warn about the risks for complications associated with its product, which may include kidney and liver damage and skeletal muscle side effects, in addition to Type 2 diabetes. Despite this information, a Lipitor recall has not been announced. Since being approved by the U.S. Food and Drug Administration (FDA) in 1996, a growing body of evidence has tied Lipitor to the above injuries. In February 2012, the agency ordered Pfizer to adjust the drug’s labeling to note its association with new-onset Type 2 diabetes.

Learn More about Lipitor Lawsuits

Attorneys at Bernstein Liebhard LLP are actively investigating Lipitor lawsuit claims on behalf of individuals who allegedly developed Type 2 diabetes after taking the cholesterol-lowering statin. Call for more information at .